Roivant Sciences Ltd. (ROIV)
NASDAQ: ROIV · Real-Time Price · USD
28.53
+1.01 (3.67%)
At close: Apr 30, 2026, 4:00 PM EDT
28.85
+0.32 (1.11%)
After-hours: Apr 30, 2026, 7:54 PM EDT
Roivant Sciences Revenue
Roivant Sciences had revenue of $2.00M in the quarter ending December 31, 2025, a decrease of -77.83%. This brings the company's revenue in the last twelve months to $13.31M, down -56.36% year-over-year. In the fiscal year ending March 31, 2025, Roivant Sciences had annual revenue of $29.05M, down -11.19%.
Revenue (ttm)
$13.31M
Revenue Growth
-56.36%
P/S Ratio
1,534.11
Revenue / Employee
$17,747
Employees
750
Market Cap
20.42B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 29.05M | -3.66M | -11.19% |
| Mar 31, 2024 | 32.71M | 1.18M | 3.75% |
| Mar 31, 2023 | 31.53M | -23.76M | -42.97% |
| Mar 31, 2022 | 55.29M | 31.49M | 132.34% |
| Mar 31, 2021 | 23.80M | -43.89M | -64.85% |
| Mar 31, 2020 | 67.69M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Incyte | 5.36B |
| Jazz Pharmaceuticals | 4.27B |
| Genmab | 3.72B |
| BioNTech SE | 3.37B |
| Royalty Pharma | 2.38B |
| Moderna | 1.94B |
| Ascendis Pharma | 845.52M |
| Insmed | 606.42M |
ROIV News
- 4 weeks ago - Roivant Sciences Transcript: Study result - Transcripts
- 4 weeks ago - Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) - GlobeNewsWire
- 4 weeks ago - Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) - GlobeNewsWire
- 4 weeks ago - New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis - GlobeNewsWire
- 7 weeks ago - Roivant Sciences Transcript: Leerink Global Healthcare Conference 2026 - Transcripts
- 2 months ago - Roivant Sciences Transcript: Status update - Transcripts
- 2 months ago - Moderna agrees to pay up to $2.25 billion to settle COVID vaccine patent dispute - Reuters
- 2 months ago - Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna - GlobeNewsWire